Drug profile · INN
trastuzumab-dttb
ONTRUZANT
trastuzumab-dttb (ONTRUZANT) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Route of administration: iv (infusion). Current US regulatory status: approved.
Drug details — trastuzumab-dttb
- US status
- approved
- Class
- —
- Route
- IV (INFUSION)
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
trastuzumab-dttb (ONTRUZANT) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Route of administration: iv (infusion). Current US regulatory status: approved.
Key facts
Mechanism of action
Receptor protein-tyrosine kinase erbB-2 inhibitor
Primary target: Receptor tyrosine-protein kinase erbB-2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is trastuzumab-dttb?
trastuzumab-dttb (ONTRUZANT) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Route of administration: iv (infusion). Current US regulatory status: approved.
What is the brand name for trastuzumab-dttb?
ONTRUZANT is a marketed brand name for trastuzumab-dttb. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trastuzumab-dttb?
trastuzumab-dttb has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.